PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2016 | 6 | 3 | A122-127
Article title

Recurrent invasive pulmonary aspergillosis or breakthrough fungal infection in a child after haploidentical hematopoietic stem cell transplantation

Authors
Content
Title variants
Languages of publication
EN
Abstracts
EN
Invasive fungal infections (IFI) are devastating and life-threatening infections affecting especially immunocompromised patients. We report on a case of a 14-year-old boy with myelodysplastic syndrome (MDS), after haploidentical hematopoietic stem cell transplantation, in whom invasive pulmonary aspergillosis (IA) was diagnosed and successfully treated with subsequent (despite the secondary antifungal prophylaxis) IA or breakthrough infection development. Thanks to intensive and broad spectrum antifungal treatment (voriconazole upfront therapy, followed by a combination of voriconazole and micafungin, and eventually by the amphotericin B lipid complex), significant improvement was accomplished.
Discipline
Publisher

Journal
Year
Volume
6
Issue
3
Pages
A122-127
Physical description
Contributors
author
  • Department of Paediatrics, Paediatric Haematology and Oncology, Independent Public Clinical Hospital No. 1, Szczecin, Poland, tociepa@gmail.com
References
  • 1. Berman JN, Look T. Pediatric Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease. In: Orkin SH, Fisher DE, Ginsburg D et al. (ed.). Nathan and Oski’s Hematology and Oncology of Infancy and Childhood. Elsevier Saunders, Philadelphia 2015: 1555-1613.
  • 2. Groll AH, Castagnola E, Cesaro S et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 2014; 15(8): e327-340.
  • 3. Wattier RL, Dvorak CC, Hoffman JA et al. A Prospective, International Cohort Study of Invasive Mold Infections in Children. J Pediatric Infect Dis Soc 2015; 4(4): 313-322.
  • 4. Domenech C, Leick-Courtois C, Bienvenu AL et al. Improvement in the Outcome of Invasive Aspergillosis in a Pediatric Hematology Department: A 10-Year Review. J Pediatr Hematol Oncol 2015; 37(7): 560-565.
  • 5. Styczynski J, Czyzewski K, Wysocki M et al. Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study. Clin Microbiol Infect 2016; 22(2): 179. e1-179.e10.
  • 6. Hope WW, Castagnola E, Groll AH et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012; 18(suppl 7): 38-52.
  • 7. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47(4): 503-509.
  • 8. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49(9): 3640-3645.
  • 9. Roilides E, Pana ZD. Application of diagnostic markers to invasive aspergillosis in children. Ann NY Acad Sci 2012; 1272: 1-8.
  • 10. Tragiannidis A, Roilides E, Walsh TJ et al. Invasive aspergillosis in children with acquired immunodeficiencies. Clin Infect Dis 2012; 54(2): 258-267.
  • 11. Kang HM, Lee HJ, Cho EY et al. The Clinical Significance of Voriconazole Therapeutic Drug Monitoring in Children With Invasive Fungal Infections. Pediatr Hematol Oncol 2015; 32(8): 557-567.
  • 12. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356(4): 348-359.
  • 13. Döring M, Müller C, Johann PD et al. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis 2012; 12: 263.
  • 14. Pagano L, Verga L, Busca A et al. Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey. J Antimicrob Chemother 2014; 69(11): 3142-3147.
  • 15. Peng XG, Dong Y, Zhang TT et al. Immune Reconstitution of CD4+T Cells after Allogeneic Hematopoietic Stem Cell Transplantation and its Correlation with Invasive Fungal Infection in Patients with Hematological Malignancies. Asian Pac J Cancer Prev 2015; 16(8): 3137-3140.
  • 16. Nikolajeva O, Mijovic A, Hess D et al. Single-donor granulocyte transfusions for improving the outcome of high-risk pediatric patients with known bacterial and fungal infections undergoing stem cell transplantation: a 10-year single-center experience. Bone Marrow Transplant 2015; 50(6): 846-849.
  • 17. Kadri SS, Remy KE, Strich JR et al. Role of granulocyte transfusions in invasive fusariosis: systematic review and single-center experience. Transfusion 2015; 55(9): 2076-2085.
  • 18. Lehrnbecher T, Kalkum M, Champer J et al. Immunotherapy in invasive fungal infection – focus on invasive aspergillosis. Curr Pharm Des 2013; 19(20): 3689-3712.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-175c5c06-c086-4398-81f7-42d00cf7fa3e
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.